Alivus Life Sciences Ltd

Alivus Life Sciences Board Meeting Date

Alivus Life Sciences scheduled a board meeting for May 14, 2026. Directors will approve annual audited results and consider a dividend recommendation for shareholders.

Alivus Life Sciences Other Announcement

Alivus Life Sciences Limited filed its Annual Secretarial Compliance Report for FY2025-26. The report confirms full regulatory compliance with no adverse observations from the practicing company secretary.

Alivus Life Sciences Debt & Borrowing

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) confirmed it is not identified as a Large Corporate for the financial year. The company reported zero outstanding borrowings as of March 31, 2026, and is therefore not required to submit incremental debt disclosures under SEBI's framework.

Alivus Life Sciences Q3 FY26 Results: Net Profit ₹150 Cr, Up 9.5% YoY

Alivus Life Sciences Ltd reported net profit of ₹150 Cr (+9.5% YoY) for Q3 FY26.

Key figure

Net profit ₹150 Cr · +9.5% YoY